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 Abstract 
Background: This prospective study examines the diagnostic and prognostic utility of tumor 
M2 pyruvate kinase (Tu-M2-PK) used in conjunction with CA 19-9 in patients with 
subsequently histologically confirmed peri-ampullary malignancy. 
Methods: Plasma Tu-M2-PK and serum CA 19-9 levels were measured at admission in a 
cohort of patients with suspected pancreatic cancer.  Values for Tu-M2-PK and serum CA 19-
9 were compared to a control group comprising jaundiced patients in whom malignancy was 
excluded by ERCP and non-jaundiced individuals undergoing laparoscopic cholecystectomy.   
Results: The mean (sd) plasma Tu-M2-PK level for patients with histologically-proven 
malignancy was 40.5 (26.4) U/ml and for non-cancer patients was 29.9 (20.9) U/ml (Mann-
Whitney U=1163, P = 0.006).  Tu-M2-PK had an AOC of 0.623 on ROC analysis and at 
optimal cut-off of 27 U/ml, sensitivity is 66%, specificity is 58%. However, on multi-variate Cox 
regression modelling elevated Tu-M2-PK (>27 u/ml) was strongly correlated with the 
subsequent finding of poorly differentiated cancer and/or metastatic disease and strongly 
predicted survival on Kaplan-Meier analysis. 
Conclusion:  An elevated Tu-M2-PK over 27 units/ml measured on admission in suspected 
peri-ampullary cancer is a predictor of adverse prognosis in peri-ampullary cancer. 
(185 words) 
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Introduction 
Pre-operative tissue diagnosis of cancer of the pancreas remains difficult.
1
  In those 
individuals with lesions arising from the ampulla of Vater, pre-operative endoscopic biopsy is 
feasible.
2
  However, for the majority of patients with pancreatic tumours, current pre-operative 
diagnosis relies on a combination of interpretative information obtained from imaging 
techniques such as trans-abdominal ultrasonograpy, endoscopic ultrasonography (EUS) and 
computed tomography (CT)
3 
augmented by information obtained from biopsy, brushings or 
sampling of pancreatic ductal juice during endoscopic retrograde cholangiopancreatography 
(ERCP).
4
  To date there is no reliable blood test for the diagnosis of pancreatic cancer. 
Sustained searches for a reliable blood test have led to the evaluation of carcinoembryonic 
antigen (CEA)
5
, carbohydrate antigen (CA) 19-9
 6, 7, 8
, and other tumour-associated antigens 
such as CA 50
6
, CA 242
9
, foetoacinar protein (FAP)
 10
 and SPAN-1
11
 amongst others, either 
alone or in combination.
12, 13, 14, 15
  Perhaps the best recognised of these is CA 19-9.
8, 10, 12 ,13., 
14 ,15,
  Although elevated in cholestasis
16,17,18
, serial sampling after relief of jaundice may be of 
value
19 
but CA 19-9 lacks sufficient discriminant value for use as a sole diagnostic test.
20, 21
 
Recent insights into tumour metabolism have shown that a wide range of human tumours 
express the enzyme pyruvate kinase, a component of the aerobic glycolysis pathways.
22
  Of 
the four different isoforms found in mammalian tissue, the M2 isoenzyme is strongly over-
expressed in cancer states and shifts from the tetrameric to the dimeric state which can be 
detected with a specific monoclonal antibody.
23
  A commercially available enzyme-linked 
immunosorbent assay (ELISA) kit has allowed for the reliable detection and quantification of 
the enzyme tumour-M2-pyruvate kinase (Tu-M2-PK) in blood.
24
  Reports suggest that Tu-M2-
PK levels may be elevated in patients with breast
25
, gastrointestinal
26
, lung 
27
and renal
28 
tumours.  The reference range for Tu-M2-PK in normal populations is well defined.
29
   
Increasing evidence suggests that Tu-M2-PK may become a valuable plasma marker for the 
diagnosis of cancer.  Oremek and co-workers have established the reference range in 666 
consecutive blood donors.
29
  However it should be noted that Oremek’s study was conducted 
using serum samples which may require a higher cut-off value than EDTA-plasma.
24
  A cut-off 
point of 22.5 U/ml in their study corresponded to a sensitivity of 71% with 90% specificity for 
the detection of cancer.  Tu-M2-PK levels are elevated in patients with breast, lung, renal and 
gastrointestinal cancer.
 25, 26, 27, 28
  At least five previous published reports
26, 29, 32, 33, 34
 have 
evaluated the role of Tu-M2-PK in the diagnosis of pancreatic cancer.  Limitations inherent in 
several previous reports have been the lack of histologic confirmation of malignancy and 
sufficiently prolonged follow-up to assess survival.  The present study follows a cohort of 
patients referred to a tertiary referral hepato-pancreatico-biliary unit with a provisional 
diagnosis of pancreatic cancer, and assesses the diagnostic and prognostic utility of Tu-M2-
PK.  
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Methods 
Study objective 
The purpose of this study was to explore the diagnostic and prognostic value of Tu-M2-PK in 
patients with peri-ampullary cancer.   
Study design 
The study was a two-stage prospective, single-centre, clinical evaluation of the diagnostic 
accuracy of plasma Tu-M2-PK (used either in conjunction with serum CA 19-9 or as a stand-
alone test) in patients with subsequently histologically confirmed peri-ampullary cancer.  In 
the first stage, diagnostic performance of Tu-M2-PK (  CA 19-9) was compared in confirmed 
cancer and confirmed non-cancer controls.  The influence of jaundice and tumour 
differentiation was explored as sub-group analyses.  In the second stage, the prognostic role 
of plasma Tu-M2-PK ( CA 19-9) was assessed using prospectively recorded survival data (up 
to 3 years follow-up with a median of 271 [2-1129] days ). 
Study population 
Patients were excluded from either stage if they were unable to give informed consent, were 
under 16 years of age, if there was subsequent confirmation of a non-pancreatic malignancy 
or if there was histologically-confirmed concurrent malignancy.  Of the non-cancer controls, 
23 had jaundice with benign disease being confirmed at endoscopic retrograde 
cholangiopancreatography (ERCP) and 44 without jaundice had normal enzymatic liver 
function tests and were undergoing elective laparoscopic cholecystectomy. 
Between July 2002 and March 2004, 104 patients were admitted to the hepato-pancreatico-
biliary service of the Manchester Royal Infirmary with suspected pancreatic cancer and were 
eligible for inclusion.  Of these patients, 49 had jaundice. Subsequent histopathological 
findings confirmed pancreatic/peri-ampullary malignancy in 76 patients, of whom 19 had 
poorly differentiated tumours and 57 had moderately or poorly differentiated tumours.  
Eighteen patients underwent resection (17%).  Seventeen patients had metastatic disease at 
time of index presentation.  The 76 patients with confirmed cancer constitute the disease 
group for subsequent comparative analyses. 
Investigations and principal outcome measures 
For the purposes of this study CA 19-9 and Tu-M2-PK levels in blood were assayed at a 
single time-point prior to resection or pancreatic biopsy in patients with clinically-suspected 
pancreatic cancer and in patients in the control groups.  The principal outcome measures 
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were estimation of the sensitivity and specificity of Tu-M2-PK (  CA 19-9) for the pre-
operative diagnosis of peri-ampullary cancer and for prediction of survival. 
Sample collection and storage 
Following informed consent, a sample of venous blood (3 ml) was drawn into an 
ethylenediaminetetraacetic acid (EDTA)-containing tube for assay.  Samples were centrifuged 
and supernatant EDTA plasma was separated within 12 hours and stored at -20ºC for Tu-M2-
PK assay.  The relevant serum samples for CA 19-9 were transported to the Department of 
Biochemistry of the Christie Hospital, Manchester where they were assayed in the regional 
clinical reference laboratory. 
Assay protocols and reference values 
Tu-M2-PK levels in EDTA-plasma samples were assayed using a commercially-available 
ELISA (ScheBo Biotech UK Ltd, Basingstoke, UK
) 30
. 
 
The Tu-M2-PK test kit allows the 
quantification of Tu-M2-PK within the range of 5 to 100 units/ml (U/ml) EDTA plasma.  Values 
out of range are specified as <5U/ml or >100U/ml respectively.  The mean intra-assay 
coeffient of variance (CV) was 3.6% (1.0-8.6%).  This compares to the published CV provided 
by the manufacturer of 3.5% (2.4-7.0%).
30
  The mean inter-assay CV was 5.4% (3.9-6.5%), 
compared to the manufacturer’s values of 5.3% (3.3-7.5%).  The analytical range for the CA 
19-9 assay extends from the minimum detectable concentration value of 0.8 to 240 U/ml.  
Samples with concentrations greater than the upper limit of this analytical range were diluted 
using a volumetric pipette with Bayer CA 19-9 assay calibrator Level 1 to bring the 
concentration within the calibration curve and re-assayed.  
Ethical approval 
The study was approved by the Manchester Research Ethics Committee and registered as a 
full clinical study with the Research and Development (R&D) office of the Manchester Royal 
Infirmary.  
Data analyses 
Data were entered into the Statistical Package for the Social Sciences, version 12.0 (SPSS, 
Chicago, Illinois, USA) for statistical analysis.  Data are presented as median (inter-quartile 
range and range) and mean (standard deviation). 
The Mann-Whitney U test was used to compare assay findings between groups, and the 
Spearman rho was used for correlations.  Youden's index
31
 (sensitivity + specificity - 1) was 
used to calculate the cut-off value for Tu-M2-PK and CA19-9 that best maximises sensitivity 
and specificity using the receiver-operating characteristic curve (ROC).  The two tests were 
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compared using the area under the curve (AUC).  Exploratory survival analysis utilised 
stepwise multivariate Cox regression and Kaplan Meier techniques.  A probability of less than 
0.05 was considered statistically significant.   
 7 
Results 
Plasma Tu-M2-PK (± CA 19-9) for diagnosis of peri-ampullary cancer 
The mean plasma Tu-M2-PK level for patients with histologically-proven malignancy was 40.5 
(26.4) U/ml and for all non-cancer patients was 29.9 (20.9) U/ml (table 1).  This difference 
was statistically significant (Mann-Whitney U=1163, P = 0.006).  The mean serum CA19-9 
level for patients with histologically-proven malignancy was 2477 (5328) U/ml and for patients 
in the control groups was 1017 (4011) U/ml (table 1).  This difference was also statistically 
significant (Mann-Whitney U=527, P < 0.001).  Summary ROC characteristics are provided in 
Figure 1. The Tu-M2-PK test with an AOC of 0.623 is unlikely to provide a useful discriminant 
test for pancreatic cancer.  At an optimal cut-off of 27.2 U/ml, sensitivity is 66%, specificity is 
58% and the positive likelihood ratio is 1.6.  CA 19-9 test with an AOC of 0.74 performs 
moderately well although unlikely to be an adequate test in isolation.  At an optimal cut-off of 
39.0 U/ml, sensitivity is 71%, specificity is 74% and the positive likelihood ratio is 2.6. 
The Tu-M2-PK test findings appear unaffected by the presence of jaundice in control patients. 
However, the CA 19-9 test findings differ markedly according to whether jaundice is present 
(table 2: sub-group analysis).  Consequently, CA 19-9 testing may only have some utility in 
those patients with suspected cancer presenting without jaundice.  
Plasma tu-M2-PK and serum CA 19-9 as prognostic markers 
The mean plasma Tu-M2-PK level for patients with histologically-proven malignancy was 40.5 
(26.4) U/ml and non-confirmed patients was 37.7 (29.3) U/ml.  This difference was not 
statistically significant (Mann-Whitney U=942, P = 0.37).  The mean serum CA19-9 level for 
patients with histologically-proven malignancy was 2477 (5328) U/ml and for patients in the 
control groups was 1513 (3770) U/ml.  This difference was also not statistically significant 
(Mann-Whitney U=1054, P=0.94). 
Sub-group analysis (Table 2) suggested that Tu-M2-PK testing on admission may have 
prognostic value in identifying individuals with metastatic disease and poorly differentiated 
tumors.  Survival data recorded for patients with confirmed cancer were used to further 
explore this finding.  The correlation structure of putative explanatory variables is shown in 
Table 3.  The correlation between age and gender reflects the older age of female patients 
(mean age 70 vs. 61).  Presence of metastatic disease and identification of a poorly 
differentiated tumour are strongly correlated.  Tu-M2-PK is seen to be correlated with poor 
differentiation and metastatic disease while CA 19-9 only correlates with metastatic disease 
and not poor differentiation (p=0.387).  Multivariate Cox regressions modelling determinants 
of survival were built stepwise including age and sex (Table 4).  Neither of these variables 
fitted at conventional levels of statistical significance but are left in subsequent models by 
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convention.  Each of the remaining four explantory variables was added individually to explore 
their influence upon survival.  Only poor tumour differentiation and Tu-M2-PK test value fitted 
in the model. Tu-M2-PK was dichotomised at the optimal cut-off (27 ml/U) and fitted as a 
binary variable in the model.  Patients with values above the cut-off were dying 2.6 times 
faster than those with values below (95%CI: 1.3 to 5.3).  A Kaplan Meier survival curve for 
high and low Tu-M2-PK values is shown in Figure 2.  Figure 3 illustrates a Kaplan meier curve 
calculated for the subgroup of patients undergoing resection. 
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Discussion 
Contemporary diagnostic algorithms for pancreatic cancer employ a range of sophisticated 
imaging and diagnostic modalities.  Integration of information from cross-sectional computed 
tomography together with findings from endoscopic retrograde cholangiopancreatography 
together with endoscopic ultrasound-guided fine-needle aspiration allows the construction of a 
logical management plan.  In the setting of tertiary care pancreatic surgery, there remains a 
need for biochemical markers with diagnostic and/or prognostic information. 
A key limitation of several previous studies has been the lack of histologic confirmation of 
malignancy in patients treated as pancreas cancer.  The present study provides a clear 
distinction between those patients in whom a histological diagnosis of cancer was confirmed 
and the cohort who were suspected of having pancreatic cancer but where the diagnosis was 
not confirmed.  A further key feature of the study population in this study is that patients with 
obstructive jaundice were positively identified as not having pancreatobiliary malignancy at 
ERCP.   
The combination of proven malignancy, proven non-malignant jaundice and follow-up until 
death make this a unique study and the largest to date that looks systematically through 
exploratory and challenge stages at the utility of Tu-M2-PK for diagnosis and prognosis in 
peri-ampullary cancer.  
There were higher levels of both Tu-M2-PK and CA 19-9 in patients with pancreatic cancer 
compared to controls (table 1).  Although Tu-M2-PK was less affected by jaundice than CA 
19-9 (table 2), the relatively poor performance of both these tests indicates that they are of 
limited value even as adjunctive diagnostic tests in a tertiary care setting.  Several studies 
have reported the utility of repeating an elevated CA 19-9 after relief of jaundice and our 
findings support this suggestion
 8,16,17
. 
The exploratory survival analysis using a binary cut-off set at 27 U/ml for Tu-M2-PK provides 
important novel findings.  Tu-M2-PK above 27 U/ml is a significant predictor of hazard of 
death (table 4) and this is observed in the Kaplan-Meier survival analysis (figure 2).  This 
differential is maintained in the subgroup undergoing resection (figure 3). 
The pathophysiologic basis of this finding is not known but as abnormalities of the aerobic 
glycolysis pathway are widespread in malignant cells, it appears that Tu-M2-PK functions as a 
metabolic marker of disseminated malignancy in this setting. 
This finding can be readily integrated into current management pathways.  Focusing on the 
tertiary care setting, the question of whether to undertake resection is increasingly based on 
the outcome of multidisciplinary discussion.  This decision is particularly problematic in more 
elderly patients, those with co-morbidity and individuals with solid tumours of the head of the 
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pancreas of 3 – 4 cm in maximal transverse diameter where the probability of achieving 
curative or R0 resection is low.  In this latter group, the risk of microscopic dissemination of  
malignancy is high. 
The findings of the present study require further verification by other workers, in particular the 
results would be substantiated by investigating the response of serial Tu-M2-PK levels in 
patients undergoing R0 resection and the relation of Tu-M2-PK to molecular genetic 
prognostic markers (Sarr MG – personal communication).  These points notwithstanding, our 
results suggest that Tu-M2-PK carried out during the pre-resection assessment phase is 
potentially a valuable predictor of poor differentiation and adverse outcome and thus may 
prove to be a valuable addition to the management of patients with peri-ampullary cancer. 
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Table 1: Demographics and test values 
 
  Suspected Cancer  Controls 
  Confirmed    Not confirmed   
  All Non-jaundiced Jaundiced    All Non-jaundiced Jaundiced 
N  76 38 38  28  67 44 23 
Age (SD)  64.9 (12.3) 62.8 (13.2) 66.9 (11.0)  62.8 (12.4)  53.4 (19.2) 48.9 (15.9) 62.0 (22.3) 
Sex (% male)  55% 53% 55%  53%  28% 23% 39% 
Tu M2-PK           
Mean (SD)  40.5 (26.4) 35.9 (23.1) 45.2 (28.9)  37.7 (29.3)  29.9 (20.9) 12.7 (7.3) 34.6 (24.7) 
Median  36 30 37  26  25 11 27 
IQR  21 – 54 19 – 49 23 – 62  18 – 45  16 – 40 7 – 18 18 – 43 
Range  0 – 105 0 – 105 8 – 105  5 – 105  0-105 4 – 35 0 – 105  
CA 19-9           
Mean (SD)  2477 (5328) 1206 (3083) 3749 (6687)  1513 (3770)  1017 (4011) 23.3 (48.3) 3003 (6602) 
Median  163 34 1127  227  12 7 140 
IQR  24 – 2244 10 – 341 129 – 2503  33 – 1438  5 – 41 4 – 20 12 – 1542 
Range  0 – 25000 0 – 16177 0 – 25000  5 – 19520  0 – 23420 0 – 219 0 – 23420 
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 Table 2: Sub-group analyses 
 
Effect of jaundice on diagnostic accuracy 
  All  Non-jaundiced  Jaundiced 
  AOC p  AOC p  AOC p 
Tu-M2-PK  0.623 .012   0.607 .099  0.605 0.18 
CA19-9  0.740 <.001  0.760 <.001  0.651 .053 
 
 
Sub-group analysis:  prognostic disease markers 
  Metastatic 
disease 
 Poor 
differentiation 
 Moderate-poor 
differentiation 
  AOC p  AOC p  AOC p 
Tu-M2-PK  0.680 .015   0.655 .035  0.574 .196 
CA19-9  0.633 .071  0.429 .910  0.531 .591 
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Table 3: Pearson correlation coefficients for  
survival analysis explanatory variables† 
 
  age sex Metastatic 
disease 
Poor 
differentiation 
Tu-M2-PK CA 19-9 
age 1 .355*** .087 -.112 .208* .210* 
sex .355*** 1 .137 .137 .157 .137 
Metastatic disease .087 .137 1 .272*** .203* .263** 
Poor differentiation  -.112 .137 .272*** 1 .208* -.101 
Tu-M2-PK .208* .157 .203* .208* 1 .169 
CA 19-9 .210* .137 .263** -.101 .169 1 
† N=76 patients 
* significant at the 0.1 level (2-tailed) 
**   significant at the 0.05 level (2-tailed). 
***  significant at the 0.01 level (2-tailed). 
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 Table 4: Exploratory survival analysis 
OUTCOME = Hazard of Death 
Dependent Variable = Survival from time of test. 
Initial Log Likelihood function: -2 Log likelihood (-2LL): 362.0 
 B SE Wald Df Sig. Exp(B) 
Base Model 
age .017 .014 1.605 1 .205 1.018 
sex -.223 .320 .486 1 .486 .800 
-2LL: 361.1; Chi-square: 1.7; DoF: 2 p: 0.43 
Incremental model: Metastatic disease 
age .017 .014 1.486 1 .223 1.017 
sex -.226 .320 .498 1 .481 .798 
MetaD .193 .337 .326 1 .568 1.212 
-2LL: 360.8; 2: 0.3; DoF: 1 p: 0.58 
Incremental model: Poorly differentiated tumour 
age .023 .014 2.564 1 .109 1.023 
sex -.382 .334 1.312 1 .252 .682 
PoorD .814 .328 6.158 1 .013 2.257 
-2LL: 355.5; 2: 7.4; DoF: 1 p: 0.018 
Incremental model: CA19-9 
age .021 .014 2.155 1 .142 1.021 
sex -.249 .323 .594 1 .441 .779 
CA19-9 .000 .000 .793 1 .373 1.000 
-2LL: 360.2; 2: 0.9; DoF: 1 p: 0.34 
Incremental model: Tu-M2-PK 
age .005 .014 .110 1 .741 1.005 
sex -.171 .313 .298 1 .585 .843 
Tu-M2-PK .021 .006 11.030 1 .001 1.021 
-2LL: 350.4; 2: 10.7; DoF: 1 p: 0.001 
Incremental model: Tu-M2-PK (binary variable, cut off 27 U/ml) 
age .017 .013 1.604 1 .205 1.017 
sex -.333 .319 1.091 1 .296 .717 
Tu-M2-PK+ .958 .361 7.039 1 .008 2.606 
-2LL: 352.8; 2: 8.3; DoF: 1 p: 0.004 
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Figure 1: Receiver operatic characteristic for cancer and non-cancer patients. 
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Figure 2: Kaplan Meier survival curve showing patients with  
high and low Tu-M2-PK test values. 
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Figure and Table legends 
 
Table 1 
Demographic profile of patients in the study.   
 
Table 2 
Sub-group analyses.  The diagnostic phase analysis examining the effect of jaundice 
is shown in patients with known cancer.  The prognostic phase results examining 
patients with metastatic disease and poorly differentiated malignancy is shown. 
 
Table 3 
Pearson correlation coefficients for survival analysis. 
 
Table 4: 
Exploratory survival analysis. 
The abbreviation poor D stands for poorly differentiated disease and the abbreviation 
meta D for metastatic disease. DoF = degrees of freedom. 
 
Figure 1 
Receiver operator characteristic for cancer and non-cancer patients. 
 
 
Figure 2: 
Kaplan-Meier survival curve for patients with Tu-M2-PK above 27 U/ml and those 
with Tu-M2-PK below 27 U/ml. 
 
Figure 3:  
Kaplan-Meier survival curve in patients undergoing resection with Tu-M2-PK above 
27 U/ml and those with Tu-M2-PK below 27 U/ml. 
 
